Select Page

165,000 dementia patients reveal hidden stroke risk from common drug

165,000 dementia patients reveal hidden stroke risk from common drug

A massive UK study of more than 165,000 dementia patients has uncovered troubling new evidence about risperidone, a commonly used drug for severe agitation. Researchers found the antipsychotic increases stroke risk in dementia patients across the board—including those with no prior heart disease or stroke—challenging the long-held belief that some patients might be safer candidates than others. Because risperidone is the only drug of its type licensed for dementia, doctors often use it as a last resort when distressing symptoms become unmanageable.

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.